Cleave Biosciences Adds $10M In Series A
Burlingame-based biopharmaceuticals developer Cleave Biosciences has raised another $10M in its Series A funding round, the firm announced today. According to Cleave, the new funding came from New Enterprise Associates. The funding brings its total raised in the Series A to $54M. Cleave's other investors include US Venture Partners, 5AM Ventures, Clarus Ventures, OrbiMed Advisors, Astellas Venture Management and Osage University Partners. The firm is focused on cancer treatments.
posted on Tuesday, April 9, 2013 (Link to more information)
Related companies:
Cleave Biosciences
Related stories:
> Cleave Biosciences Gets $37M
> Cleave Biosciences Gets $42M For Cancer Therapies
> Cell Biosciences Buys Alpha Innotech, Raises $19M
> Pacific Biosciences Raises $50M
> Imago Biosciences Sees $26.5M
silicontap.com Home